Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense
docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive
breast cancer overexpressing HER2